How to use GIP / GLP1 coagonists for therapeutic purposes

Abstract

To provide pharmaceutical compositions for use in treating obesity.SOLUTION: Provided is a pharmaceutical composition including tirzepatide or a pharmaceutically acceptable salt thereof, which is administered subcutaneously at least one escalation dose once weekly for a minimum of four weeks and at least one maintenance dose once weekly for a minimum of four weeks following the escalation dose, the escalation dose being selected from the group consisting of 2.5 mg, 7.5 mg, and 12.5 mg of tirzepatide or a pharmaceutically acceptable salt thereof, the initial dose of the escalation dose being 2.5 mg, the escalation dose being a 2.5 mg incremental increase, and the maintenance dose being selected from the group consisting of 5.0 mg, 10.0 mg, and 15.0 mg of tirzepatide or a pharmaceutically acceptable salt thereof.SELECTED DRAWING: None

Claims

1. A pharmaceutical composition for use in treating obesity, comprising tilzepatide or a pharmaceutically acceptable salt thereof, characterized in that at least one escalating dose is administered subcutaneously once a week for at least four weeks, and thereafter at least one maintenance dose is administered subcutaneously once a week for at least four weeks, wherein the escalating dose is selected from the group consisting of 2.5 mg, 7.5 mg, and 12.5 mg of tilzepatide or a pharmaceutically acceptable salt thereof, the initial dose of the escalating dose being 2.5 mg, the escalation being an increment of 2.5 mg, and the maintenance dose being selected from the group consisting of 5.0 mg, 10.0 mg, and 15.0 mg of tilzepatide or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising tilzepatide or a pharmaceutically acceptable salt thereof for use in improving weight management, characterized in that at least one escalating dose is administered subcutaneously once a week for at least four weeks, and thereafter at least one maintenance dose is administered subcutaneously once a week for at least four weeks, wherein the escalating dose is selected from the group consisting of 2.5 mg, 7.5 mg, and 12.5 mg of tilzepatide or a pharmaceutically acceptable salt thereof, the initial dose of the escalating dose being 2.5 mg, the escalation being an increment of 2.5 mg, and the maintenance dose being selected from the group consisting of 5.0 mg, 10.0 mg, and 15.0 mg of tilzepatide or a pharmaceutically acceptable salt thereof.

3. The composition according to claim 1 or 2, wherein the maintenance dose is 5.0 mg.

4. The composition according to claim 1 or 2, wherein the maintenance dose is 10.0 mg.

5. The composition according to claim 1 or 2, wherein the maintenance dose is 15.0 mg.

Images